TP53 and hepatocellular carcinoma: Preliminary mechanism explorations by GSEA and somatic variants analysis revealed that dysregulated cell cycle, purine metabolism, and TP53 mutation may play important roles resulting in poor OS outcomes of HCC patients in the high-risk group.